Cited by 466Glioma Diagnosis and TreatmentLung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Epidermal Growth Factor Receptor, Protein Kinase B/Akt, and Glioma Response to Erlotinib

Haas-Kogan, Daphne A., Prados, Michael D., Tihan, Tarik, Eberhard, David A., Jelluma, Nannette, Arvold, Nils D., Baumber, Rachel, Lamborn, Kathleen R., Kapadia, Ami, Malec, Mary, Berger, Mitchel S., Stokoe, David·2005·JNCI Journal of the National Cancer Institute

DOI 10.1093/jnci/dji161

Open this paper in CoChat — free account

Abstract

BACKGROUND: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib (also known as Tarceva or OSI-774) has shown promising response rates in malignant gliomas. We investigated the association between expression of EGFR and downstream signaling components and the response of malignant gliomas to erlotinib in a phase I trial of erlotinib administered either alone or with the alkylating agent temozolomide. METHODS: Expression of EGFR and ligand-independent EGFRvIII mutant proteins and of phosphorylated protein kinase B (PKB)/Akt in specimens from glioma patients were assessed by immunohistochemistry. EGFR gene amplification was evaluated by fluorescence in situ hybridization. Mutations in PTEN and EGFR were assessed by polymerase chain reaction amplification and sequencing. Response was evaluated by sequential magnetic resonance imaging every 2 months. The Cochran-Mantel-Haenzel test was used to assess associations between biomarker status and response. All statistical tests were two-sided. RESULTS: Of 41 glioma patients, eight responded to treatment. Response to erlotinib was associated with EGFR expression (P = .07) and EGFR amplification (P = .08). These associations were stronger and statistically significant among the 29 patients initially diagnosed with glioblastoma multiforme (P = .03 and P = .02, respectively). Among six responders with sufficient tumor tissue, none had EGFRvIII mutations. None of the 22 tumors with high levels of phosphorylated PKB/Akt responded to erlotinib treatment, whereas eight of the 18 tumors with low levels of phosphorylated PKB/Akt responded to erlotinib treatment (P < .001). The level of phosphorylated PKB/Akt was also associated with time to progression (P < .001). CONCLUSIONS: Among glioma patients, those with glioblastoma multiforme tumors who have high levels of EGFR expression and low levels of phosphorylated PKB/Akt had better response to erlotinib treatment than those with low levels of EGFR expression and high levels of phosphorylated PKB/Akt.

Integrity signals

Registry

Crossref · 10.1093/jnci/dji161

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J., Lydon, N., Kantarjian, H. M., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,237
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,695
EGFR and cancer prognosis.
Nicholson, R., Gee, J., & Harper, M. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00231-3 · Cited by 2,132
Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer
Cappuzzo, F., Hirsch, F. R., Rossi, E., Bartolini, S., Ceresoli, G. L., Bemis, L., Haney, J., Witta, S. E., Danenberg, K. D., Domenichini, I., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji112 · Cited by 1,538
Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer
Mendelsohn, J. M., & Baselga, J. M. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.504 · Cited by 1,257
ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization
Kallioniemi, O. P., Kallioniemi, A., Kurisu, W., Thor, A., Chen, L. C., Smith, H. S., Waldman, F. M., Pinkel, D., & Gray, J. W. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5321 · Cited by 555
Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder, S. L., Yakes, F. M., Muthuswamy, S. K., Bianco, R., Simpson, J. F., & Arteaga, C. L. (2001) · PubMed · Cited by 548

Show all 37 references

Research works printed but not linked: 2

Salz L, Rubin M, Hochster H, Tchekmeydian NS, Waksal H, Needle M, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc ASCO2001 (abstr); 20 : 7A .
Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortes-Funes H, Hitt R, et al. Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen. Proc ASCO2002 (abstr); 21 : 504 .

Sorted by citations

Items 101–200 of 466

Acquired Resistance to Erlotinib in A-431 Epidermoid Cancer Cells Requires Down-regulation of MMAC1/PTEN and Up-regulation of Phosphorylated Akt
Yamasaki, F., Johansen, M. J., Zhang, D., Krishnamurthy, S., Felix, E. A., Bartholomeusz, C., Aguilar, R. J., Kurisu, K., Mills, G. B., Hortobágyi, G. N., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3020 · Cited by 118
Advances in the genetics of glioblastoma: are we reaching critical mass?
Purow, B. W., & Schiff, D. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.96 · Cited by 118
Recurrent Glioblastoma: Where we stand
Roy, S., Lahiri, D., Maji, T., & Biswas, J. (2015) · South Asian Journal of Cancer · doi:10.4103/2278-330x.175953 · Cited by 112
Retracted
Glycolytic glioma cells with active glycogen synthase are sensitive to PTEN and inhibitors of PI3K and gluconeogenesis
Beckner, M. E., Gobbel, G. T., Abounader, R., Burovic, F., Agostino, N. R., Laterra, J., & Pollack, I. F. (2005) · Laboratory Investigation · doi:10.1038/labinvest.3700355 · Cited by 115
The epidermal growth factor receptor in malignant gliomas: pathogenesis and therapeutic implications
Nakamura, J. L. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.4.463 · Cited by 113
Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases
Choi, E. J., Cho, B. J., Lee, D., Hwang, Y., Chun, S. H., Kim, H. H., & Kim, I. A. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-17 · Cited by 114
Rapid Radiographic and Clinical Improvement After Treatment of a MET-Amplified Recurrent Glioblastoma With a Mesenchymal-Epithelial Transition Inhibitor
Chi, A. S., Batchelor, T. T., Kwak, E. L., Clark, J. W., Wang, D. L., Wilner, K. D., Louis, D. N., & Iafrate, A. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.4586 · Cited by 110
Therapeutic options for recurrent high-grade glioma in adult patients: Recent advances
Nieder, C., Adam, M., Molls, M., & Grosu, A. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.06.007 · Cited by 110
Gone FISHing: Clinical Lessons Learned in Brain Tumor Molecular Diagnostics over the Last Decade
Horbinski, C., Miller, C. R., & Perry, A. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2010.00453.x · Cited by 109
Targeted molecular therapies against epidermal growth factor receptor: Past experiences and challenges
Reardon, D. A., Wen, P. Y., & Mellinghoff, I. K. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou232 · Cited by 111
Designer Therapies for Glioblastoma Multiforme
Sathornsumetee, S., & Rich, J. N. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1444.009 · Cited by 110
Diagnosis and Treatment of High-Grade Astrocytoma
Sathornsumetee, S., Rich, J. N., & Reardon, D. A. (2007) · Neurologic Clinics · doi:10.1016/j.ncl.2007.07.004 · Cited by 108
Anti-Apoptosis Mechanisms in Malignant Gliomas
Ziegler, D. S., Kung, A. L., & Kieran, M. W. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9717 · Cited by 110
Molecular pathology in adult high‐grade gliomas: from molecular diagnostics to target therapies
Masui, K., Cloughesy, T. F., & Mischel, P. S. (2011) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2011.01238.x · Cited by 113
Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240
Fenton, T. R., Nathanson, D. A., de Albuquerque, C. P., Kuga, D., Iwanami, A., Dang, J. H. T., Yang, H., Tanaka, K., Oba‐Shinjo, S. M., Uno, M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1211962109 · Cited by 106
A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments
Masui, K., Gini, B., Wykosky, J., Zanca, C., Mischel, P. S., Furnari, F. B., & Cavenee, W. K. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt086 · Cited by 111
Diagnosis of malignant glioma: role of neuropathology
Brat, D. J., Prayson, R. A., Ryken, T. C., & Olson, J. J. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9618-1 · Cited by 107
Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future
Chen, R., Cohen, A. L., & Colman, H. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0418-0 · Cited by 104
Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins
Ziegler, D. S., Wright, R. D., Kesari, S., Lemieux, M. E., Tran, M. A., Jain, M., Zawel, L. S., & Kung, A. L. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34120 · Cited by 100
EGFRvIII Deletion Mutations in Pediatric High-Grade Glioma and Response to Targeted Therapy in Pediatric Glioma Cell Lines
Bax, D. A., Gaspar, N., Little, S. E., Marshall, L. V., Perryman, L., Regairaz, M., Viana‐Pereira, M., Vuononvirta, R., Sharp, S. Y., Reis-Filho, J. S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3210 · Cited by 100
An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma
Rodriguez, S. M. B., Kamel, A. E., Ciubotaru, G. V., Onose, G., Sevastre, A.-S., Sfredel, V., Dănoiu, S., Dricu, A., & Tătăranu, L. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311110 · Cited by 108
PIK3CA alterations in primary (de novo) and secondary glioblastomas
Kita, D., Yonekawa, Y., Weller, M., & Ohgaki, H. (2007) · Acta Neuropathologica · doi:10.1007/s00401-006-0186-1 · Cited by 100
Characterization of an imatinib-sensitive subset of high-grade human glioma cultures
Hägerstrand, D., Hesselager, G., Achterberg, S., Bolin, U. W., Kowanetz, M., Kastemar, M., Heldin, C., Isaksson, A., Nistér, M., & Östman, A. (2006) · Oncogene · doi:10.1038/sj.onc.1209497 · Cited by 96
A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor‐mediated apoptosis in glioblastomas
Akazawa, T., Kwatra, S. G., Goldsmith, L. E., Richardson, M. D., Cox, E. A., Sampson, J. H., & Kwatra, M. M. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06032.x · Cited by 96
Molecular Diagnostic Testing in Malignant Gliomas: A Practical Update on Predictive Markers
Yip, S. S. F., Iafrate, A. J., & Louis, D. N. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31815f65fb · Cited by 96
Oncolytic HSV and Erlotinib Inhibit Tumor Growth and Angiogenesis in a Novel Malignant Peripheral Nerve Sheath Tumor Xenograft Model
Mahller, Y. Y., Vaikunth, S. S., Currier, M. A., Miller, S. J., Ripberger, M. C., Hsu, Y., Mehrian‐Shai, R., Collins, M. H., Crombleholme, T. M., Ratner, N., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300038 · Cited by 94
Targeted Therapy for Malignant Glioma Patients: Lessons Learned and the Road Ahead
Huang, T., Sarkaria, S. M., Cloughesy, T. F., & Mischel, P. S. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2009.04.008 · Cited by 92
Cerebral gluconeogenesis and diseases
Yip, J., Geng, X., Shen, J., & Ding, Y. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00521 · Cited by 89
Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: Results of North Central Cancer Treatment Group protocol N0177
Krishnan, S., Brown, P. D., Ballman, K. V., Fiveash, J. B., Uhm, J. H., Giannini, C., Jaeckle, K. A., Geoffroy, F. J., Nabors, B., & Buckner, J. C. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.01.018 · Cited by 90
Inhibition of Glioblastoma Growth in a Highly Invasive Nude Mouse Model Can Be Achieved by Targeting Epidermal Growth Factor Receptor but not Vascular Endothelial Growth Factor Receptor-2
Martens, T., Laabs, Y., Günther, H. S., Kemming, D., Zhu, Z., Witte, L., Hagel, C., Westphal, M., & Lamszus, K. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0147 · Cited by 87
Blockage of a miR-21/EGFR regulatory feedback loop augments anti-EGFR therapy in glioblastomas
Zhang, K.-L., Han, L., Chen, L., Shi, Z., Yang, M., Ren, Y., Chen, L., Zhang, J., Pu, P., & Kang, C. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.08.043 · Cited by 87
A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients
Collaborative, B. T. T., Raizer, J. J., Giglio, P., Hu, J. L., Groves, M., Merrell, R. T., Conrad, C., Phuphanich, S., Puduvalli, V. K., Loghin, M. E., et al. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1958-z · Cited by 85
Glioblastoma update: molecular biology, diagnosis, treatment, response assessment, and translational clinical trials
Lieberman, F. S. (2017) · F1000Research · doi:10.12688/f1000research.11493.1 · Cited by 85
Worse Outcome in Primary Glioblastoma Multiforme With Concurrent Epidermal Growth Factor Receptor and p53 Alteration
Ruano, Y., Ribalta, T., de Lope, Á. R., Campos‐Martín, Y., Fiaño, C., Pérez-Magán, E., Hernández-Moneo, J.-L., Mollejo, M., & Meléndez, B. (2009) · American Journal of Clinical Pathology · doi:10.1309/ajcp64ybdvctirwv · Cited by 82
Molecular Diagnostics of Gliomas
Nikiforova, M. N., & Hamilton, R. L. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2010-0649-rair.1 · Cited by 83
Molecular pathologic diagnosis of epidermal growth factor receptor
Maire, C. L., & Ligon, K. L. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou294 · Cited by 78
Robust Detection of EGFR Copy Number Changes and EGFR Variant III: Technical Aspects and Relevance for Glioma Diagnostics
Jeuken, J. W. M., Sijben, A. E. J., Alenda, C., Rijntjes, J., Dekkers, M. M. G., Boots‐Sprenger, S., McLendon, R. E., & Wesseling, P. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00320.x · Cited by 79
Role of Receptor Tyrosine Kinases and Their Ligands in Glioblastoma
Carrasco‐García, E., Saceda, M., & Martínez-Lacaci, I. (2014) · Cells · doi:10.3390/cells3020199 · Cited by 79
Modeling Glioma Growth and Invasion in Drosophila melanogaster
Witte, H. T., Jeibmann, A., Klämbt, C., & Paulus, W. (2009) · Neoplasia · doi:10.1593/neo.09576 · Cited by 76
EGF receptor variant III as a target antigen for tumor immunotherapy
Li, G., & Wong, A. J. (2008) · Expert Review of Vaccines · doi:10.1586/14760584.7.7.977 · Cited by 74
Targeting EGFR resistance networks in head and neck cancer
Ratushny, V., Astsaturov, I. A., Burtness, B. A., Golemis, E. A., & Silverman, J. S. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2009.02.021 · Cited by 76
Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma
Zahonero, C., Aguilera‐Sepúlveda, P., Ramírez‐Castillejo, C., Pajares, M., Bolós, M. V., Cantero, D., Pérez‐Núñez, Á., Hernández‐Laín, A., Sánchez‐Gómez, P., & Sepúlveda-Sánchez, J. M. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0736 · Cited by 72
Phase I and Pharmacokinetic Studies of Erlotinib Administered Concurrently with Radiotherapy for Children, Adolescents, and Young Adults with High-Grade Glioma
Broniscer, A., Baker, S. J., Stewart, C. F., Merchant, T. E., Laningham, F. H., Schaiquevich, P. S., Koçak, M., Morris, E. B., Endersby, R., Ellison, D. W., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1923 · Cited by 73
EGFR-dependent mechanisms in glioblastoma: towards a better therapeutic strategy
Zahonero, C., & Sánchez‐Gómez, P. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1608-1 · Cited by 71
Identification of survival‐related genes of the phosphatidylinositol 3′‐kinase signaling pathway in glioblastoma multiforme
Ruano, Y., Mollejo, M., Camacho, F. I., de Lope, Á. R., Fiaño, C., Ribalta, T., Martínez, P., Hernández-Moneo, J.-L., & Meléndez, B. (2008) · Cancer · doi:10.1002/cncr.23338 · Cited by 71
Individualized Targeted Therapy for Glioblastoma
Weller, M., Stupp, R., Hegi, M. E., & Wick, W. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e318243f6c9 · Cited by 69
Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions
Patel, M. D., Vogelbaum, M. A., Barnett, G. H., Jalali, R., & Ahluwalia, M. S. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.703177 · Cited by 74
Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): What have we learned so far?
Fischer, B. E., Marinov, M., & Arcaro, A. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.01.006 · Cited by 67
Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab
Lv, S., Teugels, E., Sadones, J., Brakeleer, S. D., Duerinck, J., Four, S. D., Michotte, A., Grève, J. D., & Neyns, B. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1539 · Cited by 67
Molecular Advances of Brain Tumors in Radiation Oncology
Noda, S., El-Jawahri, A. R., Patel, D., Lautenschlaeger, T., Siedow, M. R., & Chakravarti, A. (2009) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2009.02.005 · Cited by 66
Malignant glioma drug discovery – targeting protein kinases
Sathornsumetee, S., Vredenburgh, K. A., Lattimore, K. P., & Rich, J. N. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.1.1 · Cited by 65
Analysis of EGFR overexpression, EGFR gene amplification and the EGFRvIII mutation in Portuguese high-grade gliomas.
Viana‐Pereira, M., Lopes, J. M., Little, S., Milanezi, F., Basto, D., Pardal, F., Jones, C., & Reis, R. M. (2008) · PubMed · Cited by 67
Gemcitabine Combined with Gefitinib in Patients with Inoperable or Metastatic Pancreatic Cancer: A Phase II Study of the Hellenic Cooperative Oncology Group with Biomarker Evaluation
Fountzilas, G., Bobos, M., Kalogera‐Fountzila, A., Xiros, N., Murray, S. J., Linardou, H., Karayannopoulou, G., Koutras, A. K., Bafaloukos, D. I., Samantas, E., et al. (2008) · Cancer Investigation · doi:10.1080/07357900801918611 · Cited by 65
Akt Phosphorylation at Ser473 Predicts Benefit of Paclitaxel Chemotherapy in Node-Positive Breast Cancer
Yang, S. X., Costantino, J. P., Kim, C., Mamounas, E. P., Nguyen, D., Jeong, J., Wolmark, N., Kidwell, K., Paik, S., & Swain, S. M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.1602 · Cited by 65
Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110
Schulte, A., Liffers, K., Kathagen, A., Riethdorf, S., Zapf, S., Merlo, A., Kolbe, K., Westphal, M., & Lamszus, K. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not093 · Cited by 65
Mutational profiling of kinases in glioblastoma
Bleeker, F. E., Lamba, S., Zanon, C., Molenaar, R. J., Hulsebos, T. J. M., Troost, D., van Tilborg, A. A., Vandertop, W. P., Leenstra, S., Noorden, C. J. F. V., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-718 · Cited by 67
Relationship ofEGFRMutations, Expression, Amplification, and Polymorphisms to Epidermal Growth Factor Receptor Inhibitors in the NCI60 Cell Lines
Liu, W., Wu, X., Zhang, W., Montenegro, R. C., Fackenthal, D. L., Spitz, J. A., Huff, L. M., Innocenti, F., Das, S., Cook, E. H., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0547 · Cited by 64
Angiogenesis and Anti-Angiogenic Molecularly Targeted Therapies in Malignant Gliomas
Argyriou, A. A., Giannopoulou, E., & Kalofonos, H. P. (2009) · Oncology · doi:10.1159/000218165 · Cited by 61
EGFR Inhibition in Glioma Cells Modulates Rho Signaling to Inhibit Cell Motility and Invasion and Cooperates with Temozolomide to Reduce Cell Growth
Ramis, G., Thomàs‐Moyà, E., de Mattos, S. F., Rodríguez, J., & Villalonga, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038770 · Cited by 63
Retracted
Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy
Pantaleo, M. A., Nannini, M., Maleddu, A., Fanti, S., Ambrosini, V., Nanni, C., Boschi, S., & Biasco, G. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.10.001 · Cited by 61
Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variables
Bai, Y., Tolles, J., Cheng, H., Siddiqui, S., Gopinath, A., Pectasides, E., Camp, R. L., Rimm, D. L., & Molinaro, A. M. (2011) · Laboratory Investigation · doi:10.1038/labinvest.2011.75 · Cited by 60
Cyclopamine cooperates with EGFR inhibition to deplete stem-like cancer cells in glioblastoma-derived spheroid cultures
Eimer, S., Dugay, F., Airiau, K., Avril, T., Quillien, V., Belaud‐Rotureau, M., & Belloc, F. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos266 · Cited by 60
Radiomics in gliomas: clinical implications of computational modeling and fractal-based analysis
Jang, K., Russo, C., & Ieva, A. D. (2020) · Neuroradiology · doi:10.1007/s00234-020-02403-1 · Cited by 58
Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma
Minner, S. J. P., Rump, D., Tennstedt, P., Simon, R., Burandt, E., Terracciano, L., Moch, H., Wilczak, W., Bokemeyer, C., Fisch, M., et al. (2011) · Cancer · doi:10.1002/cncr.26436 · Cited by 59
Current overview of the role of Akt in cancer studies via applied immunohistochemistry
Shtilbans, V., Wu, M., & Burstein, D. E. (2008) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2007.12.001 · Cited by 59
Efficacy of osimertinib against EGFRvIII+ glioblastoma
Chagoya, G., Kwatra, S. G., Nanni, C., Roberts, C. M., Phillips, S. M., Nullmeyergh, S., Gilmore, S. P., Spasojević, I., Corcoran, D. L., Young, C. C., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27599 · Cited by 60
Targeted molecular therapy of malignant gliomas
Kesari, S., Ramakrishna, N. R., Sauvageot, C., Stiles, C. D., & Wen, P. Y. (2005) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-005-0046-8 · Cited by 59
Genome-Scale Signatures of Gene Interaction from Compound Screens Predict Clinical Efficacy of Targeted Cancer Therapies
Jiang, P., Lee, W., Li, X., Johnson, C., Liu, J. S., Brown, M. A., Aster, J. C., & Liu, X. S. (2018) · Cell Systems · doi:10.1016/j.cels.2018.01.009 · Cited by 55
ANGIOGENESIS AND GLIOMAS
Jouanneau, E. (2008) · Neurosurgery · doi:10.1227/01.neu.0000311060.65002.4e · Cited by 60
Molecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and Treatment
Rizzo, D., Ruggiero, A., Martini, M., Rizzo, V., Maurizi, P., & Riccardi, R. (2015) · BioMed Research International · doi:10.1155/2015/215135 · Cited by 59
New approaches to primary brain tumor treatment
Sathornsumetee, S., & Rich, J. N. (2006) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000231473.00030.1f · Cited by 55
Angiogenesis in Gliomas: Imaging and Experimental Therapeutics
Gagner, J., Law, M., Fischer, I., Newcomb, E. W., & Zagzag, D. (2005) · Brain Pathology · doi:10.1111/j.1750-3639.2005.tb00119.x · Cited by 55
Receptor Tyrosine Kinases: Principles and Functions in Glioma Invasion
Nakada, M., Kita, D., Teng, L., Pyko, I. V., Watanabe, T., Hayashi, Y., & Hamada, J. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-4719-7_8 · Cited by 54
Clinical experience with gefitinib: An update
Cappuzzo, F., Finocchiaro, G., Metro, G., Bartolini, S., Magrini, E., Cancellieri, A., Trisolini, R., Castaldini, L., Tallini, G., & CRINO, L. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.08.008 · Cited by 54
Heme oxygenase-1 expression in human gliomas and its correlation with poor prognosis in patients with astrocytoma
Gandini, N. A., Fermento, M. E., Salomón, D. G., Obiol, D. J., Andrés, N. C., Zenklusen, J. C., Arévalo, J., Blasco, J., Romero, A. L., Facchinetti, M. M., et al. (2013) · Tumor Biology · doi:10.1007/s13277-013-1373-z · Cited by 53
Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death
Ronellenfitsch, M. W., Brucker, D. P., Burger, M. C., Wolking, S., Tritschler, F., Rieger, J., Wick, W., Weller, M., & Steinbach, J. P. (2009) · Brain · doi:10.1093/brain/awp093 · Cited by 53
Therapeutic advances for glioblastoma multiforme: Current status and future prospects
Robins, H. I., Chang, S. M., Butowski, N. A., & Mehta, M. P. (2007) · Current Oncology Reports · doi:10.1007/bf02951428 · Cited by 51
Candidate genes for sensitivity and resistance of human glioblastoma multiforme cell lines to erlotinib
Halatsch, M., Low, S. H. H., Mursch, K., Hielscher, T., Schmidt, U. I., Unterberg, A. W., Vougioukas, V. I., & Feuerhake, F. (2009) · Journal of neurosurgery · doi:10.3171/2008.9.jns08551 · Cited by 52
Inhibiting kinases in malignant gliomas
Chi, A. S., & Wen, P. Y. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.4.473 · Cited by 51
Glioblastoma therapy: going beyond Hercules Columns
Mangiola, A., Anile, C., Pompucci, A., Capone, G., Rigante, L., & BONIS, P. D. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.158 · Cited by 50
Control of proliferation in astrocytoma cells by the receptor tyrosine kinase/PI3K/AKT signaling axis and the use of PI-103 and TCN as potential anti-astrocytoma therapies
Gursel, D. B., Connell-Albert, Y., Tuskan, R. G., Anastassiadis, T., Walrath, J. C., Hawes, J. J., Schaick, J. C. A.-V., & Reilly, K. M. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor035 · Cited by 48
Targeting multiple kinases in glioblastoma multiforme
Sathornsumetee, S., & Reardon, D. A. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780802692603 · Cited by 49
Prognostic but not predictive role of platelet‐derived growth factor receptors in patients with recurrent glioblastoma
Paulsson, J., Lindh, M. B., Jarvius, M., Puputti, M., Nistér, M., Nupponen, N. N., Paulus, W., Söderberg, O., Dresemann, G. P., von Deimling, A., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25528 · Cited by 49
Neurooncology clinical trial design for targeted therapies: Lessons learned from the North American Brain Tumor Consortium
Chang, S. M., Lamborn, K. R., Kuhn, J. G., Yung, W. K. A., Gilbert, M. R., Wen, P. Y., Fine, H. A., Mehta, M. P., DeAngelis, L. M., Lieberman, F. S., et al. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-021 · Cited by 48
Review on clinical trials of targeted treatments in malignant mesothelioma
Jakobsen, J. N., & Sørensen, J. B. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1655-3 · Cited by 48
Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy
Shchors, K., Persson, A. I., Rostker, F., Tihan, T., Lyubynska, N., Li, N., Swigart, L. B., Berger, M. S., Hanahan, D., Weiss, W. A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219142110 · Cited by 49
Schweinfurthin A Selectively Inhibits Proliferation and Rho Signaling in Glioma and Neurofibromatosis Type 1 Tumor Cells in a NF1-GRD–Dependent Manner
Turbyville, T. J., Gursel, D. B., Tuskan, R. G., Walrath, J. C., Lipschultz, C. A., Lockett, S., Wiemer, D. F., Beutler, J. A., & Reilly, K. M. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0834 · Cited by 47
Clinical Significance of Molecular Biomarkers in Glioblastoma
Ang, C., Guiot, M.-C., Ramanakumar, A. V., Roberge, D., & Kavan, P. (2010) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100010805 · Cited by 46
Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy
Abounader, R. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.9.2.235 · Cited by 48
The Effect of Molecular Diagnostics on the Treatment of Glioma
Bush, N. A. O., & Butowski, N. A. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0585-6 · Cited by 47
Glial Progenitors as Targets for Transformation in Glioma
Ilkhanizadeh, S., Lau, J., Huang, M., Foster, D. J., Wong, R. A., Frantz, A., Wang, S., Weiss, W. A., & Persson, A. I. (2014) · Advances in cancer research · doi:10.1016/b978-0-12-800249-0.00001-9 · Cited by 47
Radiosensitizing effects of gefitinib at different administration times in vitro
Zhuang, H., Sun, J. Y., Yuan, Z., Wang, J., Zhao, L., Wang, P., Ren, X., & Wang, C. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01190.x · Cited by 46
PLXDC1 (TEM7) is identified in a genome-wide expression screen of glioblastoma endothelium
Beaty, R. M., Edwards, J. B., Boon, K., Siu, I., Conway, J. E., & Riggins, G. J. (2006) · Journal of Neuro-Oncology · doi:10.1007/s11060-006-9227-9 · Cited by 47
Enzyme-Transporter-Mediated Drug Interactions with Small Molecule Tyrosine Kinase Inhibitors
Shao, J., Markowitz, J. S., Bei, D., & An, G. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24113 · Cited by 46
Prognostic and Predictive Biomarkers in Adult and Pediatric Gliomas: Toward Personalized Treatment
Haynes, H. R., Camelo-Piragua, S. I., & Kurian, K. M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00047 · Cited by 45
The Role of PTEN in Tumor Angiogenesis
Rodriguez, S., & Huynh‐Do, U. (2011) · Journal of Oncology · doi:10.1155/2012/141236 · Cited by 44
Radiosensitization of Primary Human Glioblastoma Stem-like Cells with Low-Dose AKT Inhibition
Mehta, M., Khan, A. J., Danish, S. F., Haffty, B. G., & Sabaawy, H. E. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0708 · Cited by 47
Prospective evaluation of angiogenic, hypoxic and EGFR‐related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan
Hasselbalch, B., Eriksen, J. G., Broholm, H., Christensen, I. J., Grunnet, K., Horsman, M. R., Poulsen, H. S., Stockhausen, M., & Lassen, U. (2010) · Apmis · doi:10.1111/j.1600-0463.2010.02631.x · Cited by 43
Canine Astrocytic Tumors
Stoica, G., Levine, J., Wolff, J. E. A., & Murphy, K. (2010) · Veterinary Pathology · doi:10.1177/0300985810389543 · Cited by 43
Potential Role of Preoperative Conventional MRI Including Diffusion Measurements in Assessing Epidermal Growth Factor Receptor Gene Amplification Status in Patients with Glioblastoma
Young, R. J., Gupta, A. K., Shah, A. D., Graber, J. J., Schweitzer, A. D., Prager, A. J., Shi, W., Zhang, Z., Huse, J. T., & Omuro, A. M. P. (2013) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3604 · Cited by 43

Authors: Haas-Kogan, D. A., Prados, M. D., Tihan, T., Eberhard, D. A., Jelluma, N., Arvold, N. D., Baumber, R., Lamborn, K. R., Kapadia, A., Malec, M., Berger, M. S., & Stokoe, D.
Affiliations: University of California, San Francisco (US)
Corresponding author: Haas-Kogan, Daphne A.
ORCID: Haas-Kogan, Daphne A.
Prados, Michael D.
Jelluma, Nannette
Arvold, Nils D.
Baumber, Rachel
Berger, Mitchel S.
Stokoe, David
Venue: JNCI Journal of the National Cancer Institute
Publisher: Oxford University Press (OUP)
Published: 2005-06-15
Volume: 97
Issue: 12
Pages: 880-887
ISSN: 0027-8874 (ISSN-L)
1460-2105
DOI: 10.1093/jnci/dji161
OpenAlex: W2104743043
Cited by: 465
References: 37
Citations by year: 2026: 3 · 2025: 2 · 2024: 4 · 2023: 8 · 2022: 4 · 2021: 4 · 2020: 9 · 2019: 5 · 2018: 7 · 2017: 13 · 2016: 6 · 2015: 17 · 2014: 24 · 2013: 27 · 2012: 34
FWCI: 22.18
Type: journal article
Language: en
Open access: closed
Locations: JNCI Journal of the National Cancer Institute (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (5m01rr000079-42)
National Cancer Institute (P50CA097257)
National Institute of Neurological Disorders and Stroke (P01NS042927, P01 NS42927)
National Center for Research Resources (M01 RR-00079)
Topics: Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords: erlotinib, EGFR tyrosine kinase inhibitors, high-grade glioma, glioblastoma, EGFR amplification, EGFRvIII, Akt phosphorylation, Akt, temozolomide, predictive biomarkers, treatment response, PTEN mutation, time to progression
MeSH terms: Erlotinib Hydrochloride, Temozolomide, Adult, Aged, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Dacarbazine, Drug Administration Schedule, Female, Glioma, Humans, Immunohistochemistry, Male, Middle Aged, Mutation, Phosphoric Monoester Hydrolases, Phosphorylation, Proto-Oncogene Proteins, Quinazolines, Supratentorial Neoplasms, Protein Serine-Threonine Kinases, In Situ Hybridization, Fluorescence, Drug Resistance, Neoplasm, Area Under Curve, Tumor Suppressor Proteins, Proto-Oncogene Proteins c-akt, PTEN Phosphohydrolase, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Epidermal Growth Factor Receptor, Protein Kinase B/Akt, and Glioma Response to Erlotinib

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks